menu

Practice Changing Studies in Metastatic Hormone-Sensitive Prostate Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

2022 Spring & Summer Conference Coverage: Integrating Prostate Cancer Data into Clinical Practice

Practice Changing Studies in Metastatic Hormone-Sensitive Prostate Cancer

Minute CME/CE
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
of 1.00 program credits
Claim credits How to claim
Credits Claimed -
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    In this program, expert faculty review and discuss real-world applications of practice-changing data on the treatment of prostate cancer presented at the 2022 ASCO Genitourinary Cancers Symposium and the 2022 ASCO Annual Meeting.

  • Target Audience

    This activity has been designed to meet the educational needs of oncologists, urologists, advance practice nurses, physician assistants and pharmacists involved in the treatment of patients with prostate cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Evaluate recent practice-changing data presented at ASCO meetings and its clinical impact
    2. Apply recently presented data from scientific congresses into clinical practice to expand treatment options, mitigate toxicity and improve outcomes for patients
  • Format

    Internet

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and TotalCME, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008162-9999-22-106-H01-P
    Type of Activity: Knowledge

    Note: Pharmacists must complete all episodes in this activity to claim credit.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

    Note: Nurses must complete all episodes in this activity to claim credit.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

    Rana McKay, MD, faculty for this educational event receives grant/research support from Pfizer, Tempus, and Bayer; and is on consultant/advisory board for AstraZenca, Aveo, Bayer, Bristol Myers Squib, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, and Tempus.

    Daniel P. Petrylak, MD, faculty for this educational event receives consulting fees from Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, and Urogen; receives grant support from Ada Cap (Advanced Accelerator Applications), Agensys Inc, *Astellas, AstraZeneca, *Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, *Eli Lilly, *Endocyte, Genentech, Gilead Sciences, *Innocrin, MedImmune, Medivation, Merck, Mirati, *Novartis, Pfizer, *Progenics, Replimune, Roche, *Sanofi Aventis, Seattle Genetics (*Denotes study trials that have terminated); and had ownership interest/investment in Bellicum (Sold 7/2020), Tyme (sold 10/2019)

    Fred Saad MD FRCS, faculty for this educational event receives grant/research support from Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Novartis, Sanofi, and Pfizer; is on speakers bureau/honoraria for non-CME for Amgen, Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Novartis, Sanofi, Pfizer, and Tolmar; and is on consultant/advisory board for Amgen, Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Novartis, Sanofi, Pfizer, Tolmar

    Matthew R. Smith, MD, PhD, faculty for this educational event receives grant/research support for his institution from Amgen, Bayer, Janssen, Lilly, and Pfizer; is on consultant/advisory board for Amgen, Bayer, Janssen, Lilly, and Pfizer

    All the relevant financial relationships for these individuals have been mitigated.

  • Planners and Managers Disclosure List

    The PIM planners and managers for this educational event, have no relevant financial relationships with ineligible companies. 
    The TotalCME planners and managers for this educational event, have no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Acknowledgement

    This activity is supported by independent educational grants from Bayer HealthCare Pharmaceuticals Inc. and Merck Sharp & Dohme.
    Jointly provided by Postgraduate Institute for Medicine and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
How To Claim Credit
Minute CME/CE is a short-form content that puts you in control of the education you consume.
Profession

Engage in Content

Click Claim Button

Track Your Status

Upon completion of Program Evaluation, your certificate will automatically appear. You may check the status of all credits claimed and certificates received by visiting your Profile.
Schedule25 Sep 2022
Webpack App